297 related articles for article (PubMed ID: 25855703)
1. Clinical and Economic Impact of Empirical Extended-Infusion Piperacillin-Tazobactam in a Community Medical Center.
Brunetti L; Poustchi S; Cunningham D; Toscani M; Nguyen J; Lim J; Ding Y; Nahass RG
Ann Pharmacother; 2015 Jul; 49(7):754-60. PubMed ID: 25855703
[TBL] [Abstract][Full Text] [Related]
2. Rationale and evidence for extended infusion of piperacillin-tazobactam.
Kaufman SE; Donnell RW; Hickey WS
Am J Health Syst Pharm; 2011 Aug; 68(16):1521-6. PubMed ID: 21817083
[TBL] [Abstract][Full Text] [Related]
3. The Retrospective Cohort of Extended-Infusion Piperacillin-Tazobactam (RECEIPT) study: a multicenter study.
Yost RJ; Cappelletty DM;
Pharmacotherapy; 2011 Aug; 31(8):767-75. PubMed ID: 21923603
[TBL] [Abstract][Full Text] [Related]
4. Extended-Infusion versus standard-infusion piperacillin-tazobactam for sepsis syndromes at a tertiary medical center.
Cutro SR; Holzman R; Dubrovskaya Y; Chen XJ; Ahuja T; Scipione MR; Chen D; Papadopoulos J; Phillips MS; Mehta SA
Antimicrob Agents Chemother; 2014 Aug; 58(8):4470-5. PubMed ID: 24867975
[TBL] [Abstract][Full Text] [Related]
5. Clinical Outcomes of Extended Versus Intermittent Infusion of Piperacillin/Tazobactam in Critically Ill Patients: A Prospective Clinical Trial.
Fan SY; Shum HP; Cheng WY; Chan YH; Leung SM; Yan WW
Pharmacotherapy; 2017 Jan; 37(1):109-119. PubMed ID: 27888542
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of an alternative extended-infusion piperacillin-tazobactam dosing strategy for the treatment of gram-negative infections.
Winstead EM; Ratliff PD; Hickson RP; Mueller JE; Judd WR
Int J Clin Pharm; 2016 Oct; 38(5):1087-93. PubMed ID: 27333796
[TBL] [Abstract][Full Text] [Related]
7. Outcomes of extended-infusion piperacillin-tazobactam: a retrospective analysis of critically ill patients.
Lee GC; Liou H; Yee R; Quan CF; Neldner K
Clin Ther; 2012 Dec; 34(12):2297-300. PubMed ID: 23195962
[TBL] [Abstract][Full Text] [Related]
8. Outcomes of an extended-infusion piperacillin-tazobactam protocol implementation in a community teaching hospital adult intensive care unit.
Schmees PM; Bergman SJ; Strader BD; Metzke ME; Pointer S; Valenti KM
Am J Health Syst Pharm; 2016 Jun; 73(11 Suppl 3):S100-5. PubMed ID: 27208142
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of ceftolozane/tazobactam plus metronidazole compared with piperacillin/tazobactam as empiric therapy for the treatment of complicated intra-abdominal infections based on the in-vitro surveillance of bacterial isolates in the UK.
Prabhu V; Foo J; Ahir H; Sarpong E; Merchant S
J Med Econ; 2017 Aug; 20(8):840-849. PubMed ID: 28532194
[TBL] [Abstract][Full Text] [Related]
10. Clinical outcomes of extended versus intermittent administration of piperacillin/tazobactam for the treatment of hospital-acquired pneumonia: a randomized controlled trial.
Bao H; Lv Y; Wang D; Xue J; Yan Z
Eur J Clin Microbiol Infect Dis; 2017 Mar; 36(3):459-466. PubMed ID: 27796647
[TBL] [Abstract][Full Text] [Related]
11. Comparative costs of ertapenem and piperacillin-tazobactam in the treatment of diabetic foot infections.
Tice AD; Turpin RS; Hoey CT; Lipsky BA; Wu J; Abramson MA
Am J Health Syst Pharm; 2007 May; 64(10):1080-6. PubMed ID: 17494908
[TBL] [Abstract][Full Text] [Related]
12. Clinical efficacy and pharmacoeconomics of a continuous-infusion piperacillin-tazobactam program in a large community teaching hospital.
Grant EM; Kuti JL; Nicolau DP; Nightingale C; Quintiliani R
Pharmacotherapy; 2002 Apr; 22(4):471-83. PubMed ID: 11939682
[TBL] [Abstract][Full Text] [Related]
13. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy.
Lodise TP; Lomaestro B; Drusano GL
Clin Infect Dis; 2007 Feb; 44(3):357-63. PubMed ID: 17205441
[TBL] [Abstract][Full Text] [Related]
14. Comparison of acute renal injury associated with intermittent and extended infusion piperacillin/tazobactam.
McCormick H; Tomaka N; Baggett S; Heierman T; LaFosse J; Gilbert S; Imhof K
Am J Health Syst Pharm; 2015 Jun; 72(11 Suppl 1):S25-30. PubMed ID: 25991590
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of ceftolozane/tazobactam compared with piperacillin/tazobactam as empiric therapy based on the in-vitro surveillance of bacterial isolates in the United States for the treatment of complicated urinary tract infections.
Kauf TL; Prabhu VS; Medic G; Borse RH; Miller B; Gaultney J; Sen SS; Basu A
BMC Infect Dis; 2017 Apr; 17(1):314. PubMed ID: 28454524
[TBL] [Abstract][Full Text] [Related]
16. Implementation of an extended-infusion piperacillin-tazobactam program at an urban teaching hospital.
Xamplas RC; Itokazu GS; Glowacki RC; Grasso AE; Caquelin C; Schwartz DN
Am J Health Syst Pharm; 2010 Apr; 67(8):622-8. PubMed ID: 20360589
[TBL] [Abstract][Full Text] [Related]
17. Pharmacoeconomics of piperacillin/tazobactam and imipenem/cilastatin in the treatment of patients with intra-abdominal infections.
Jhee SS; Gill MA; Yellin AE; Berne TV; Heseltine PN; Appleman MD
Clin Ther; 1995; 17(1):126-35. PubMed ID: 7758055
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the safety of piperacillin-tazobactam extended infusion in pediatric cystic fibrosis patients.
Riggsbee D; Engdahl S; Pettit RS
Pediatr Pulmonol; 2023 Apr; 58(4):1092-1099. PubMed ID: 36593628
[TBL] [Abstract][Full Text] [Related]
19. Outcomes of extended infusion piperacillin/tazobactam for documented Gram-negative infections.
Patel GW; Patel N; Lat A; Trombley K; Enbawe S; Manor K; Smith R; Lodise TP
Diagn Microbiol Infect Dis; 2009 Jun; 64(2):236-40. PubMed ID: 19500529
[TBL] [Abstract][Full Text] [Related]
20. Impact of a Dynamic Microbiological Environment on the Clinical Efficacy of Ertapenem and Piperacillin/Tazobactam in the Treatment of Complicated Community-Acquired Intra-Abdominal Infection in Spain: A Cost-Consequence Analysis.
Grau S; Lozano V; Valladares A; Cavanillas R; Xie Y; Nocea G
Appl Health Econ Health Policy; 2015 Aug; 13(4):369-79. PubMed ID: 25761545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
